The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. · 2019
Read The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). by Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6632213.txt.
Introduction
Cohen and co-authors present a consensus statement on immunotherapy for head and neck squamous cell cancer. Their guideline appears in the Journal for ImmunoTherapy of Cancer. These cancers kill about 380,000 people each year worldwide. Patients with recurrent or metastatic disease had few options. In 2016 the FDA approved two anti-PD-1 drugs for them. Nivolumab and pembrolizumab followed platinum treatment failure. First-line approval for pembrolizumab came later.
An expert panel from the Society for Immunotherapy of Cancer wrote the guidance. It covers patient selection for checkpoint inhibitors. It addresses treatment sequencing and response monitoring. Managing immune side effects gets detailed attention. So does PD-L1 biomarker testing. The panel limited its scope to FDA-approved drugs.
Catalog record
| CREATOR | Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 138 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) By Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, Barbara Burtness, Maura L Gillison, Kevin J Harrington, Quynh-Thu Le, Nancy Y Lee, Rom Leidner, Rebecca L Lewis, Lisa Licitra, Hisham Mehanna Published in: Journal for Immunotherapy of Cancer DOI: 10.1186/s40425-019-0662-5 ABSTRACT Abstract Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a foundation to assist clinicians’ understanding of the role of immunotherapies in this disease setting, and to standardize utilization across the field for patient benefit. Due to country-specific variances in approvals, availability and regulations regarding the discussed agents, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S. Electronic supplementary material The online version of this article (10.1186/s40425-019-0662-5) contains supplementary material, which is available to authorized users. Keywords: Guidelines, Immunotherapy, Head and neck cancer, Head and neck squamous cell carcinoma (HNSCC), Immune checkpoint inhibitor (ICI) INTRODUCTION Squamous cell carcinoma of the head and neck (HNSCC) is the 9th leading cancer by incidence worldwide and constitutes 90% of all head and neck cancers [1, 2]. In the US, approximately 50,000 new cases of HNSCC and more than 10,000 deaths occur per year [3–6]. HNSCC is a biologically diverse and genomically heterogeneous disease that arises from the squamous mucosal lining of the upper aerodigestive tract, including the lip and oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, larynx and hypopharynx [5, 7–10]. In addition to traditional risk factors including smoking and alcohol consumption, over the last two to three decades it has become apparent that the human papillomavirus (HPV) and Epstein Barr Virus (EBV) are associated with development of squamous cell carcinoma of the oropharynx and nasopharynx, respectively [11–18]. Most patients present with locally advanced disease with a high risk of recurrence, and approximately 10% of HNSCC patients present with metastatic disease [19]. Surgical resection of the primary tumor and draining lymph nodes followed by risk-adapted adjuvant radiation, with or without platinum-based chemotherapy, or primary definitive concurrent chemoradiation, remain the principal treatments employed for locally advanced HNSCC. It is important to note that multimodality treatment often drastically impacts patient quality of life (QOL) [20]. Despite advances in surgery and radiotherapy, five-year survival rates for patients (excluding EBV-related nasopharyngeal) with HNSCC across all stages remain 40–50% for tumors caused by traditional carcinogens (HPV-negative). The median overall survival (OS) for patients with recurrent/metastatic (R/M) disease is 10–13 months [19, 21–25]. The current standard of care (SOC) for locally recurrent disease (without surgical or radiation treatment options) and/or metastatic disease in the first-line setting has been platinum-based doublet chemotherapy with cetuximab. Compared to chemotherapy alone, the addition of cetuximab in the regimen described extends median progression free survival (PFS) from 3.3 months to 5.6 months (HR 0.54; P < 0.001), median OS from 7.4 months to 10.1 months (HR 0.80; P = 0.04), and response rates from 20 to 36% (P < 0.001) [26]. Furthermore, until recently, second-line treatment options included only cetuximab, methotrexate, and a taxane, each of which is associated with response proportions of 10–13%, and median PFS of 2–3 months, and without clear demonstration of an improvement in OS [27–30]. In 2016, the US Food and Drug Administration (FDA) approved two immunotherapeutic agents, the anti-programmed cell death protein (PD-1) monoclonal antibodies, nivolumab (Opdivo, Bristol-Myers Squibb) and pembrolizumab (Keytruda, Merck), for the treatment of patients with R/M HNSCC refractory to platinum-based therapy. In 2019, the FDA approved pembrolizumab for the first-line treatment of patients with unresectable R/M HNSCC. For frontline therapy, pembrolizumab was approved for use in combination with platinum and fluorouracil for all patients with R/M HNSCC and as a single agent for patients whose tumors express PD-L1 with a combined positive score (CPS) ≥1 as determined by an FDA-approved test. The FDA also expanded the intended use for the PD-L1 IHC 22C3 pharmDx kit to include use as a companion diagnostic for selecting patients with HNSCC for treatment with pembrolizumab as a single agent. Immunotherapies are designed to enhance immune system activity to eradicate cancerous cells [31]. Immune checkpoint inhibitors (ICIs) are a widely effective class of immunotherapies that block inhibitory immune checkpoint pathways in order to reactivate immune responses against cancer. Ligation of the PD-1 protein, which can be expressed by T cells, by PD-L1, often expressed by tumor cells, results in suppression of T cell immunological responses and serves as a mechanism of tumor immune evasion. Anti-PD-1/PD-L1 ICIs can block suppressive signaling through the PD-1/PD-L1 pathway and enhance antitumor immune activity [32–34]. There is an urgent need to improve treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). A better understanding of emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing, are needed to guide improvements in care. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) established the Cancer Immunotherapy Guideline - Head and Neck Cancer subcommittee to provide evidence-based recommendations on how best to incorporate immunotherapies into practice for the treatment of patients with HNSCC. This panel - including expert physicians, nurses, scientists, and a patient advocate - regularly communicated via email, teleconference, and in-person between May and November 2018 to refine the utilization and incorporation of data from available literature and clinical trials into the development of an HNSCC-specific consensus management guideline. These resulting recommendations are meant to